Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORTHO-NOVUM 7/7/7-21 vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combined hormonal contraceptive; primarily suppresses ovulation via inhibition of gonadotropin release (LH and FSH) from the pituitary. Also induces changes in cervical mucus and endometrium.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy in women who elect to use an oral contraceptive
Prevention of pregnancy
One tablet orally once daily for 21 days, followed by 7 days of no tablets. Each tablet contains norethindrone 0.5 mg/0.75 mg/1 mg and ethinyl estradiol 35 mcg, with biphasic or triphasic dosing per cycle.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Ethinyl estradiol: 13-27 hours; norethindrone: 8-14 hours; with multiple dosing, steady state after 5-7 days.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Metabolized primarily by CYP3A4; norethindrone undergoes reduction and conjugation; ethinyl estradiol undergoes hydroxylation and glucuronidation.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal: <10% unchanged; biliary/fecal: ~50% as metabolites; extensive enterohepatic recirculation.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Ethinyl estradiol: 95-98% bound to albumin and SHBG; norethindrone: 60-70% bound to SHBG and albumin.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Ethinyl estradiol: 2.5-4 L/kg; norethindrone: 3.5-5 L/kg; indicates extensive tissue distribution.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: ~40-50% for ethinyl estradiol (first-pass metabolism); ~60-70% for norethindrone.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment (GFR 30-89 m L/min). Not recommended for severe renal impairment (GFR <30 m L/min) due to potential fluid retention and electrolyte disturbances.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; no specific dose adjustment, but monitor for signs of hepatic toxicity.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not indicated for use before menarche. Post-menarche adolescents: same dosing as adults. Weight-based adjustments not established; use standard adult regimen.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for postmenopausal women. Use in perimenopausal women: standard dosing with consideration of increased thrombotic risk and comorbidities.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive use. This risk increases with age, especially in women over 35 years, and with the number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders (e.g., venous thromboembolism, stroke, myocardial infarction),Hepatic disease (e.g., jaundice, liver tumors),Hypertension,Carbohydrate and lipid metabolism effects,Headache/migraine,Bleeding irregularities,Depression,Gallbladder disease,Hereditary angioedema,Pregnancy and postpartum use,Ophthalmic complaints (contact lens intolerance, retinal thrombosis)
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
High risk of arterial or venous thrombotic diseases (e.g., known thrombophilia, history of DVT/PE, cerebrovascular disease, coronary artery disease),Current or history of breast cancer or other estrogen-sensitive cancer,Hepatic adenoma or carcinoma, or active liver disease,Undiagnosed abnormal uterine bleeding,Pregnancy,Hypersensitivity to any component,Smoking and age >35 years,Hypertension uncontrolled or with vascular disease,Migraine with aura if >35 years,Diabetes with nephropathy, retinopathy, neuropathy, or other vascular disease
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No significant food interactions. Grapefruit juice may increase estrogen exposure; avoid large amounts. Taking with food can reduce nausea.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Combined hormonal contraceptives like ORTHO-NOVUM 7/7/7-21 are contraindicated in pregnancy. First trimester exposure is not associated with major malformations based on current data, but there is a small increased risk of cardiovascular and limb defects. Second and third trimester exposure has been associated with fetal harm including masculinization of female genitalia (due to progestin) and potential long-term effects. Use during pregnancy is not indicated; if pregnancy occurs, discontinue immediately.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Combined hormonal contraceptives may reduce milk production and quality, especially in early postpartum. Small amounts of estrogen and progestin are excreted in breast milk; the M/P ratio is not well defined for this specific formulation. Use is generally not recommended during breastfeeding, particularly before weaning or beyond 6 weeks postpartum when milk supply is established. Alternatives (progestin-only) are preferred.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Not applicable; this drug is contraindicated during pregnancy. No dose adjustments are made for pregnancy as it is not used in that setting. Pharmacokinetic changes of pregnancy (e.g., increased clearance) are not relevant because use is avoided.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
This triphasic oral contraceptive contains norethindrone and ethinyl estradiol. The 7/7/7-21 regimen uses three different hormone doses over 21 days followed by 7 placebo pills. Monitor for breakthrough bleeding, especially during dose transitions. Assess for contraindications including history of DVT, PE, migraine with aura, breast cancer, liver disease, or age >35 with smoking. Consider CYP3A4 interactions; rifampin, certain anticonvulsants, and St. John's wort may reduce efficacy.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one pill daily at the same time; missing pills increases pregnancy risk.,Start pack on first day of period or first Sunday after; use backup contraception for first 7 days if starting later.,Common side effects: nausea, breast tenderness, breakthrough bleeding; usually improve within 3 cycles.,Do not smoke while taking this medication; smoking increases risk of serious cardiovascular side effects.,Seek emergency care if signs of blood clot: sudden leg pain/swelling, chest pain, shortness of breath, severe headache, vision changes.,Some medications (antibiotics, seizure meds, St. John's wort) may decrease effectiveness; inform all healthcare providers.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORTHO-NOVUM 7/7/7-21 vs ALYACEN 1/35, answered by our medical review team.
ORTHO-NOVUM 7/7/7-21 is a Oral Contraceptive that works by Combined hormonal contraceptive; primarily suppresses ovulation via inhibition of gonadotropin release (LH and FSH) from the pituitary. Also induces changes in cervical mucus and endometrium.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORTHO-NOVUM 7/7/7-21 and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORTHO-NOVUM 7/7/7-21 is: One tablet orally once daily for 21 days, followed by 7 days of no tablets. Each tablet contains norethindrone 0.5 mg/0.75 mg/1 mg and ethinyl estradiol 35 mcg, with biphasic or triphasic dosing per cycle.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORTHO-NOVUM 7/7/7-21 and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORTHO-NOVUM 7/7/7-21 is classified as Category C. Combined hormonal contraceptives like ORTHO-NOVUM 7/7/7-21 are contraindicated in pregnancy. First trimester exposure is not associated with major malformations based on current da. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.